250 related articles for article (PubMed ID: 33328392)
1. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model.
Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X
J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
3. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
4. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
Ang WX; Li Z; Chi Z; Du SH; Chen C; Tay JC; Toh HC; Connolly JE; Xu XH; Wang S
Oncotarget; 2017 Feb; 8(8):13545-13559. PubMed ID: 28088790
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.
Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444
[TBL] [Abstract][Full Text] [Related]
7. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
[TBL] [Abstract][Full Text] [Related]
9. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
10. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
11. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
12. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
[TBL] [Abstract][Full Text] [Related]
13. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
14. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
15. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
16. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
Qin D; Li D; Zhang B; Chen Y; Liao X; Li X; Alexander PB; Wang Y; Li QJ
Oncoimmunology; 2020 Aug; 9(1):1806009. PubMed ID: 32923168
[TBL] [Abstract][Full Text] [Related]
17. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
18. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
[TBL] [Abstract][Full Text] [Related]
19. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
